Selected research
Industry Research
Therapeutic Radiopharmaceuticals Industry Research Report 2026
Market perspective
The global Therapeutic Radiopharmaceuticals market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Therapeutic Radiopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Therapeutic Radiopharmaceuticals is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Therapeutic Radiopharmaceuticals is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Therapeutic Radiopharmaceuticals include Aurobindo Pharma, China Isotope & Radiation, Curium Pharmaceuticals, Dongcheng, International Isotopes, Jubilant Radiopharma, Lantheus, Mundipharma and Q BioMed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Therapeutic Radiopharmaceuticals market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Therapeutic Radiopharmaceuticals Market by Company
Aurobindo Pharma
China Isotope & Radiation
Curium Pharmaceuticals
Dongcheng
International Isotopes
Jubilant Radiopharma
Lantheus
Mundipharma
Q BioMed
Bayer
Novartis
Therapeutic Radiopharmaceuticals Segment by Type
Lutetium-177
Radium-223
Iodine-131
Other
Therapeutic Radiopharmaceuticals Segment by Application
Bone Metastasis
Thyroid
Lymphoma
Other
Therapeutic Radiopharmaceuticals Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Therapeutic Radiopharmaceuticals manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Therapeutic Radiopharmaceuticals by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Therapeutic Radiopharmaceuticals in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Lutetium-177
- Radium-223
- Iodine-131
- Other
Applications
- Bone Metastasis
- Thyroid
- Lymphoma
- Other
Companies covered
- Aurobindo Pharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Dongcheng
- International Isotopes
- Jubilant Radiopharma
- Lantheus
- Mundipharma
- Q BioMed
- Bayer
- Novartis
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Therapeutic Radiopharmaceuticals Market Size (2021-2032)
- 2.2.2 Global Therapeutic Radiopharmaceuticals Sales (2021-2032)
- 2.2.3 Global Therapeutic Radiopharmaceuticals Market Average Price (2021-2032)
- 2.3 Therapeutic Radiopharmaceuticals by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Lutetium-177
- 2.3.3 Radium-223
- 2.3.4 Iodine-131
- 2.3.5 Other
- 2.4 Therapeutic Radiopharmaceuticals by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Bone Metastasis
- 2.4.3 Thyroid
- 2.4.4 Lymphoma
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Therapeutic Radiopharmaceuticals Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Therapeutic Radiopharmaceuticals Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Therapeutic Radiopharmaceuticals Revenue of Manufacturers (2021-2026)
- 3.4 Global Therapeutic Radiopharmaceuticals Average Price by Manufacturers (2021-2026)
- 3.5 Global Therapeutic Radiopharmaceuticals Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Therapeutic Radiopharmaceuticals, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Therapeutic Radiopharmaceuticals, Product Type & Application
- 3.8 Global Manufacturers of Therapeutic Radiopharmaceuticals, Established Date
- 3.9 Global Therapeutic Radiopharmaceuticals Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aurobindo Pharma
- 4.1.1 Aurobindo Pharma Company Information
- 4.1.2 Aurobindo Pharma Business Overview
- 4.1.3 Aurobindo Pharma Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Aurobindo Pharma Therapeutic Radiopharmaceuticals Product Portfolio
- 4.1.5 Aurobindo Pharma Recent Developments
- 4.2 China Isotope & Radiation
- 4.2.1 China Isotope & Radiation Company Information
- 4.2.2 China Isotope & Radiation Business Overview
- 4.2.3 China Isotope & Radiation Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 China Isotope & Radiation Therapeutic Radiopharmaceuticals Product Portfolio
- 4.2.5 China Isotope & Radiation Recent Developments
- 4.3 Curium Pharmaceuticals
- 4.3.1 Curium Pharmaceuticals Company Information
- 4.3.2 Curium Pharmaceuticals Business Overview
- 4.3.3 Curium Pharmaceuticals Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Curium Pharmaceuticals Therapeutic Radiopharmaceuticals Product Portfolio
- 4.3.5 Curium Pharmaceuticals Recent Developments
- 4.4 Dongcheng
- 4.4.1 Dongcheng Company Information
- 4.4.2 Dongcheng Business Overview
- 4.4.3 Dongcheng Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dongcheng Therapeutic Radiopharmaceuticals Product Portfolio
- 4.4.5 Dongcheng Recent Developments
- 4.5 International Isotopes
- 4.5.1 International Isotopes Company Information
- 4.5.2 International Isotopes Business Overview
- 4.5.3 International Isotopes Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 International Isotopes Therapeutic Radiopharmaceuticals Product Portfolio
- 4.5.5 International Isotopes Recent Developments
- 4.6 Jubilant Radiopharma
- 4.6.1 Jubilant Radiopharma Company Information
- 4.6.2 Jubilant Radiopharma Business Overview
- 4.6.3 Jubilant Radiopharma Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jubilant Radiopharma Therapeutic Radiopharmaceuticals Product Portfolio
- 4.6.5 Jubilant Radiopharma Recent Developments
- 4.7 Lantheus
- 4.7.1 Lantheus Company Information
- 4.7.2 Lantheus Business Overview
- 4.7.3 Lantheus Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lantheus Therapeutic Radiopharmaceuticals Product Portfolio
- 4.7.5 Lantheus Recent Developments
- 4.8 Mundipharma
- 4.8.1 Mundipharma Company Information
- 4.8.2 Mundipharma Business Overview
- 4.8.3 Mundipharma Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Mundipharma Therapeutic Radiopharmaceuticals Product Portfolio
- 4.8.5 Mundipharma Recent Developments
- 4.9 Q BioMed
- 4.9.1 Q BioMed Company Information
- 4.9.2 Q BioMed Business Overview
- 4.9.3 Q BioMed Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Q BioMed Therapeutic Radiopharmaceuticals Product Portfolio
- 4.9.5 Q BioMed Recent Developments
- 4.10 Bayer
- 4.10.1 Bayer Company Information
- 4.10.2 Bayer Business Overview
- 4.10.3 Bayer Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bayer Therapeutic Radiopharmaceuticals Product Portfolio
- 4.10.5 Bayer Recent Developments
- 4.11 Novartis
- 4.11.1 Novartis Company Information
- 4.11.2 Novartis Business Overview
- 4.11.3 Novartis Therapeutic Radiopharmaceuticals Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Novartis Therapeutic Radiopharmaceuticals Product Portfolio
- 4.11.5 Novartis Recent Developments
5 Global Therapeutic Radiopharmaceuticals Market Scenario by Region
- 5.1 Global Therapeutic Radiopharmaceuticals Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Therapeutic Radiopharmaceuticals Sales by Region: 2021-2032
- 5.2.1 Global Therapeutic Radiopharmaceuticals Sales by Region: 2021-2026
- 5.2.2 Global Therapeutic Radiopharmaceuticals Sales by Region: 2027-2032
- 5.3 Global Therapeutic Radiopharmaceuticals Revenue by Region: 2021-2032
- 5.3.1 Global Therapeutic Radiopharmaceuticals Revenue by Region: 2021-2026
- 5.3.2 Global Therapeutic Radiopharmaceuticals Revenue by Region: 2027-2032
- 5.4 North America Therapeutic Radiopharmaceuticals Market Facts & Figures by Country
- 5.4.1 North America Therapeutic Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Therapeutic Radiopharmaceuticals Sales by Country (2021-2032)
- 5.4.3 North America Therapeutic Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Therapeutic Radiopharmaceuticals Market Facts & Figures by Country
- 5.5.1 Europe Therapeutic Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Therapeutic Radiopharmaceuticals Sales by Country (2021-2032)
- 5.5.3 Europe Therapeutic Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Therapeutic Radiopharmaceuticals Market Facts & Figures by Country
- 5.6.1 Asia Pacific Therapeutic Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Therapeutic Radiopharmaceuticals Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Therapeutic Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Therapeutic Radiopharmaceuticals Market Facts & Figures by Country
- 5.7.1 South America Therapeutic Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Therapeutic Radiopharmaceuticals Sales by Country (2021-2032)
- 5.7.3 South America Therapeutic Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Therapeutic Radiopharmaceuticals Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Therapeutic Radiopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Therapeutic Radiopharmaceuticals Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Therapeutic Radiopharmaceuticals Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Therapeutic Radiopharmaceuticals Sales by Type (2021-2032)
- 6.1.1 Global Therapeutic Radiopharmaceuticals Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Therapeutic Radiopharmaceuticals Sales Market Share by Type (2021-2032)
- 6.2 Global Therapeutic Radiopharmaceuticals Revenue by Type (2021-2032)
- 6.2.1 Global Therapeutic Radiopharmaceuticals Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Therapeutic Radiopharmaceuticals Revenue Market Share by Type (2021-2032)
- 6.3 Global Therapeutic Radiopharmaceuticals Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Therapeutic Radiopharmaceuticals Sales by Application (2021-2032)
- 7.1.1 Global Therapeutic Radiopharmaceuticals Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Therapeutic Radiopharmaceuticals Sales Market Share by Application (2021-2032)
- 7.2 Global Therapeutic Radiopharmaceuticals Revenue by Application (2021-2032)
- 7.2.1 Global Therapeutic Radiopharmaceuticals Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Therapeutic Radiopharmaceuticals Revenue Market Share by Application (2021-2032)
- 7.3 Global Therapeutic Radiopharmaceuticals Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Therapeutic Radiopharmaceuticals Value Chain Analysis
- 8.1.1 Therapeutic Radiopharmaceuticals Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Therapeutic Radiopharmaceuticals Production Mode & Process
- 8.2 Therapeutic Radiopharmaceuticals Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Therapeutic Radiopharmaceuticals Distributors
- 8.2.3 Therapeutic Radiopharmaceuticals Customers
9 Global Therapeutic Radiopharmaceuticals Analyzing Market Dynamics
- 9.1 Therapeutic Radiopharmaceuticals Industry Trends
- 9.2 Therapeutic Radiopharmaceuticals Industry Drivers
- 9.3 Therapeutic Radiopharmaceuticals Industry Opportunities and Challenges
- 9.4 Therapeutic Radiopharmaceuticals Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst